“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Zoran Zdraveski Biography and Net Worth

Insider of TScan Therapeutics

Dr. Zoran Zdraveski is a Chief Legal Officer at TScan Therapeutics, Inc. Dr. Zdraveski was previously employed as a Secretary & Chief Legal Officer by Magenta Therapeutics, Inc. and a Vice President & Associate General Counsel by Epizyme, Inc. He received his undergraduate degree from Southern Methodist University, a graduate degree from Suffolk University Law School and a doctorate degree from Massachusetts Institute of Technology.

What is Zoran Zdraveski's net worth?: The estimated net worth of Zoran Zdraveski is at least $20,797.56 as of August 23rd, 2024. Dr. Zdraveski owns 4,716 shares of TScan Therapeutics stock worth more than $20,798 as of November 17th. This net worth estimate does not reflect any other assets that Dr. Zdraveski may own. Learn More about Zoran Zdraveski's net worth.
How do I contact Zoran Zdraveski?: The corporate mailing address for Dr. Zdraveski and other TScan Therapeutics executives is 830 WINTER STREET, WALTHAM MA, 02451. TScan Therapeutics can also be reached via phone at 857-399-9500 and via email at [email protected]. Learn More on Zoran Zdraveski's contact information.
Has Zoran Zdraveski been buying or selling shares of TScan Therapeutics?: Zoran Zdraveski has not been actively trading shares of TScan Therapeutics during the last quarter. Most recently, Zoran Zdraveski sold 164,686 shares of the business's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a transaction totalling $951,885.08. Following the completion of the sale, the insider now directly owns 4,716 shares of the company's stock, valued at $27,258.48. Learn More on Zoran Zdraveski's trading history.
Who are TScan Therapeutics' active insiders?: TScan Therapeutics' insider roster includes Gavin MacBeath (Insider), Brian Silver (CFO), and Zoran Zdraveski (Insider). Learn More on TScan Therapeutics' active insiders.
Are insiders buying or selling shares of TScan Therapeutics?: In the last year, TScan Therapeutics insiders bought shares 5 times. They purchased a total of 48,830 shares worth more than $248,928.70. In the last year, insiders at the sold shares 1 times. They sold a total of 164,686 shares worth more than $951,885.08. The most recent insider tranaction occured on September, 23rd when Director Barbara Klencke bought 5,000 shares worth more than $26,450.00. Insiders at TScan Therapeutics own 2.8% of the company. Learn More about insider trades at TScan Therapeutics.
Information on this page was last updated on 9/23/2024.

Zoran Zdraveski Insider Trading History at TScan Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/23/2024	Sell	164,686	$5.78	$951,885.08	4,716
9/23/2021	Buy	4,716	$7.48	$35,275.68

Zoran Zdraveski Buying and Selling Activity at TScan Therapeutics

TScan Therapeutics Company Overview

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $4.41

$4.31

$4.85

50 Day Range

MA: $5.31

$4.41

$5.94

2 Week Range

Now: $4.41

$3.73

$9.69

Volume

244,150 shs

Average Volume

253,751 shs

Market Capitalization

$233.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79